Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Use of immunesuppressant receptor
US8945557B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945557-B2 |
| Application number | US-201213661717-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 26, 2012 |
| Priority date | Oct 21, 2004 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for potentiating an immune response comprising: administering to a subject in need thereof an effective amount of an antagonist of a protein, said protein having the amino acid sequence of any one of SEQ ID NOs: 1 to 6, wherein the antagonist is an isolated monoclonal antibody or fragment thereof that specifically binds to a protein having the amino acid sequence of any one of SEQ ID NOs: 1 to 6. 2. The method of claim…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945557B2 cover?
- The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, …
- Who is the assignee on this patent?
- Ono Pharmaceutical Co
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).